Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease

Sachiko Nakaoka, Tatsuro Ishizaki, Hisashi Urushihara, Toshihiko Satoh, Shunya Ikeda, Kaoru Morikawa, Takeo Nakayama

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective The ergot-derived dopamine agonists, cabergoline and pergolide, are associated with valvulopathy risk. In Japan, product labels were revised in April 2007 to recommend periodic echocardiography for patients taking these dopamine agonists, however, the compliance of physicians to follow through with this recommendation is unknown. This study assessed changes in echocardiography evaluation of patients with Parkinson's disease (PD) taking cabergoline or pergolide before and after the label revision and examined the factors related with echocardiography performance. Methods and Patients Medical claim data from January 2005 to December 2008 were used. Patients were divided into a C-P group (prescribed either cabergoline or pergolide) or reference group (prescribed other anti-PD drugs), and further classified based on whether they were prescribed these drugs "pre-revision" or "post-revision." The Cochran-Armitage trend test was used to compare the proportion of echocardiograms obtained amongst these groups before and after the revision. The frequencies of echocardiograms performed among the treatment groups for each period were compared by Fisher's exact test. Results A total of 222 subjects (C-P, 73; reference, 149) were assessed. The proportion of C-P patients undergoing echocardiography increased from 4.8% to 27.9% after revision of product labels (p=0.001), which was higher than those in the reference group following label revisions (11.0%) (p=0.014). Prescription duration of C-P after the revision was longer in the patients with echocardiography than without echocardiography (p=0.026). Conclusion Although echocardiography evaluations increased, more than 70% of PD patients prescribed cabergoline or pergolide did not undergo such assessment despite the product label recommendation. Adherence to drug safety recommendations should be facilitated with more feasible and effective measures.

Original languageEnglish
Pages (from-to)687-694
Number of pages8
JournalInternal Medicine
Volume50
Issue number7
DOIs
Publication statusPublished - 2011
Externally publishedYes

Fingerprint

Dopamine Agonists
Parkinson Disease
Echocardiography
Pergolide
Pharmaceutical Preparations
Compliance
Prescriptions
Japan
Physicians
Safety
cabergoline

Keywords

  • Database research
  • Dopamine agonist
  • Echocardiography
  • Parkinson's disease
  • Safety information
  • Valvulopathy

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease. / Nakaoka, Sachiko; Ishizaki, Tatsuro; Urushihara, Hisashi; Satoh, Toshihiko; Ikeda, Shunya; Morikawa, Kaoru; Nakayama, Takeo.

In: Internal Medicine, Vol. 50, No. 7, 2011, p. 687-694.

Research output: Contribution to journalArticle

Nakaoka, Sachiko ; Ishizaki, Tatsuro ; Urushihara, Hisashi ; Satoh, Toshihiko ; Ikeda, Shunya ; Morikawa, Kaoru ; Nakayama, Takeo. / Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease. In: Internal Medicine. 2011 ; Vol. 50, No. 7. pp. 687-694.
@article{43acb9ada1a34aa3b9364012ed0c7269,
title = "Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease",
abstract = "Objective The ergot-derived dopamine agonists, cabergoline and pergolide, are associated with valvulopathy risk. In Japan, product labels were revised in April 2007 to recommend periodic echocardiography for patients taking these dopamine agonists, however, the compliance of physicians to follow through with this recommendation is unknown. This study assessed changes in echocardiography evaluation of patients with Parkinson's disease (PD) taking cabergoline or pergolide before and after the label revision and examined the factors related with echocardiography performance. Methods and Patients Medical claim data from January 2005 to December 2008 were used. Patients were divided into a C-P group (prescribed either cabergoline or pergolide) or reference group (prescribed other anti-PD drugs), and further classified based on whether they were prescribed these drugs {"}pre-revision{"} or {"}post-revision.{"} The Cochran-Armitage trend test was used to compare the proportion of echocardiograms obtained amongst these groups before and after the revision. The frequencies of echocardiograms performed among the treatment groups for each period were compared by Fisher's exact test. Results A total of 222 subjects (C-P, 73; reference, 149) were assessed. The proportion of C-P patients undergoing echocardiography increased from 4.8{\%} to 27.9{\%} after revision of product labels (p=0.001), which was higher than those in the reference group following label revisions (11.0{\%}) (p=0.014). Prescription duration of C-P after the revision was longer in the patients with echocardiography than without echocardiography (p=0.026). Conclusion Although echocardiography evaluations increased, more than 70{\%} of PD patients prescribed cabergoline or pergolide did not undergo such assessment despite the product label recommendation. Adherence to drug safety recommendations should be facilitated with more feasible and effective measures.",
keywords = "Database research, Dopamine agonist, Echocardiography, Parkinson's disease, Safety information, Valvulopathy",
author = "Sachiko Nakaoka and Tatsuro Ishizaki and Hisashi Urushihara and Toshihiko Satoh and Shunya Ikeda and Kaoru Morikawa and Takeo Nakayama",
year = "2011",
doi = "10.2169/internalmedicine.50.4344",
language = "English",
volume = "50",
pages = "687--694",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "7",

}

TY - JOUR

T1 - Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease

AU - Nakaoka, Sachiko

AU - Ishizaki, Tatsuro

AU - Urushihara, Hisashi

AU - Satoh, Toshihiko

AU - Ikeda, Shunya

AU - Morikawa, Kaoru

AU - Nakayama, Takeo

PY - 2011

Y1 - 2011

N2 - Objective The ergot-derived dopamine agonists, cabergoline and pergolide, are associated with valvulopathy risk. In Japan, product labels were revised in April 2007 to recommend periodic echocardiography for patients taking these dopamine agonists, however, the compliance of physicians to follow through with this recommendation is unknown. This study assessed changes in echocardiography evaluation of patients with Parkinson's disease (PD) taking cabergoline or pergolide before and after the label revision and examined the factors related with echocardiography performance. Methods and Patients Medical claim data from January 2005 to December 2008 were used. Patients were divided into a C-P group (prescribed either cabergoline or pergolide) or reference group (prescribed other anti-PD drugs), and further classified based on whether they were prescribed these drugs "pre-revision" or "post-revision." The Cochran-Armitage trend test was used to compare the proportion of echocardiograms obtained amongst these groups before and after the revision. The frequencies of echocardiograms performed among the treatment groups for each period were compared by Fisher's exact test. Results A total of 222 subjects (C-P, 73; reference, 149) were assessed. The proportion of C-P patients undergoing echocardiography increased from 4.8% to 27.9% after revision of product labels (p=0.001), which was higher than those in the reference group following label revisions (11.0%) (p=0.014). Prescription duration of C-P after the revision was longer in the patients with echocardiography than without echocardiography (p=0.026). Conclusion Although echocardiography evaluations increased, more than 70% of PD patients prescribed cabergoline or pergolide did not undergo such assessment despite the product label recommendation. Adherence to drug safety recommendations should be facilitated with more feasible and effective measures.

AB - Objective The ergot-derived dopamine agonists, cabergoline and pergolide, are associated with valvulopathy risk. In Japan, product labels were revised in April 2007 to recommend periodic echocardiography for patients taking these dopamine agonists, however, the compliance of physicians to follow through with this recommendation is unknown. This study assessed changes in echocardiography evaluation of patients with Parkinson's disease (PD) taking cabergoline or pergolide before and after the label revision and examined the factors related with echocardiography performance. Methods and Patients Medical claim data from January 2005 to December 2008 were used. Patients were divided into a C-P group (prescribed either cabergoline or pergolide) or reference group (prescribed other anti-PD drugs), and further classified based on whether they were prescribed these drugs "pre-revision" or "post-revision." The Cochran-Armitage trend test was used to compare the proportion of echocardiograms obtained amongst these groups before and after the revision. The frequencies of echocardiograms performed among the treatment groups for each period were compared by Fisher's exact test. Results A total of 222 subjects (C-P, 73; reference, 149) were assessed. The proportion of C-P patients undergoing echocardiography increased from 4.8% to 27.9% after revision of product labels (p=0.001), which was higher than those in the reference group following label revisions (11.0%) (p=0.014). Prescription duration of C-P after the revision was longer in the patients with echocardiography than without echocardiography (p=0.026). Conclusion Although echocardiography evaluations increased, more than 70% of PD patients prescribed cabergoline or pergolide did not undergo such assessment despite the product label recommendation. Adherence to drug safety recommendations should be facilitated with more feasible and effective measures.

KW - Database research

KW - Dopamine agonist

KW - Echocardiography

KW - Parkinson's disease

KW - Safety information

KW - Valvulopathy

UR - http://www.scopus.com/inward/record.url?scp=79953740339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953740339&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.50.4344

DO - 10.2169/internalmedicine.50.4344

M3 - Article

C2 - 21467699

AN - SCOPUS:79953740339

VL - 50

SP - 687

EP - 694

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 7

ER -